Anti-CD277 antibodies

Patent metadata

Field	Value
Publication number	US-11904004-B2
Application number	US-202016896556-A
Country	US
Kind code	B2
Filing date	Jun 9, 2020
Priority date	Dec 15, 2010
Publication date	Feb 20, 2024
Grant date	Feb 20, 2024

Abstract

Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

First claim

The invention claimed is:

1. A nucleic acid encoding at least the VH and VL domains of the anti-CD277 antibody, wherein said nucleic acid comprising the coding sequences of the following CDRs:

Amino acid sequence

H-CDR1
RYYMY (SEQ ID NO: 27)

H-CDR2
EINPNNGGTKFNEKFKN (SEQ ID

NO: 28)

H-CDR3
EDDYDGTPFAMDY (SEQ ID

NO: 29)

L-CDR1
HASQNINVWLS (SEQ ID NO: 30)

L-CDR2
KASNLHT (SEQ ID NO: 31)

L-CDR3
QQGQTYPYT (SEQ ID NO: 32)

2. The nucleic acid of claim 1 , wherein said nucleic acid comprises DNA sequences encoding HCDR-1 of SEQ ID NO:21, H-CDR2 of SEQ ID NO:22, HCDR-3 of SEQ ID NO:23, LCDR-1 of SEQ ID NO:24, L-CDR2 of SEQ ID NO:25, L-CDR-3 of SEQ ID NO:26.

3. The nucleic acid of claim 1 , wherein said nucleic acid comprises VH and VL coding sequences of SEQ ID NO:33 and SEQ ID NO:35 respectively.

4. An expression vector comprising the nucleic acid of claim 1 .

5. A transformed host cell comprising the nucleic acid of claim 1 , wherein said transformed host cell expresses said anti-CD277 antibody.

6. A method for producing an anti-CD277 antibody, said method comprising:
(i) culturing a transformed host cell comprising a nucleic acid of claim 1 , under conditions suitable to allow expression of an anti-CD277 antibody,
(ii) recovering said expressed anti-CD277 antibody.

7. A nucleic acid encoding an anti-CD277 antibody, said nucleic acid having the coding sequences of the CDRs of mAb7.2, said mAb7.2 being obtained from the hybridoma accessible under CNCM deposit number I-4401.

8. The nucleic acid of claim 7 , wherein said anti-CD277 antibody is a murine antibody mAb7.2 as obtained from the hybridoma accessible under CNCM deposit number I-4401.

9. An expression vector comprising the nucleic acid of claim 7 .

10. A transformed host cell comprising the nucleic acid of claim 7 , wherein said transformed host cell expresses said anti-CD277 antibody.

11. A method for producing an anti-CD277 antibody, said method comprising:
(i) culturing a transformed host cell comprising a nucleic acid of claim 7 , under conditions suitable to allow expression of an anti-CD277 antibody,
(iii) recovering said expressed anti-CD277 antibody.

Assignees

• Inst Nat Sante Rech Med
• Univ Aix Marseille
• Inst Jean Paoli & Irene Calmettes
• Centre Nat Rech Scient
• Univ Nantes
• Inst Nat Sante Rech Med
• Centre Nat Rech Scient

Inventors

• Olive Daniel
• Bonneville Marc
• Scotet Emmanuel
• Harly Christelle
• Guillaume Yves

Classifications

• A61K39/001129 Primary

  Molecules with a "CD" designation not provided for elsewhere · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K2317/55

  Fab or Fab' · CPC title